CSIMarket
 
Cadrenal Therapeutics Inc   (CVKD)
Other Ticker:  
 
 
Price: $0.3899 $-0.02 -3.728%
Day's High: $0.4074 Week Perf: -11.85 %
Day's Low: $ 0.38 30 Day Perf: -33.46 %
Volume (M): 178 52 Wk High: $ 3.14
Volume (M$): $ 69 52 Wk Avg: $0.87
Open: $0.41 52 Wk Low: $0.36



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Cadrenal Therapeutics Inc
Cadrenal Therapeutics Inc is a biotechnology company focused on developing innovative therapies for the treatment of kidney diseases. The company aims to address the unmet medical needs in this field by developing novel drugs that can improve patients' outcomes and quality of life. Cadrenal Therapeutics Inc leverages groundbreaking research and cutting-edge technologies to discover and develop new therapeutic approaches. The company's mission is to transform the treatment landscape for kidney diseases and provide hope to patients suffering from these conditions.


   Company Address: 822 A1A North Ponte Vedra 32082 FL
   Company Phone Number: 300-0701   Stock Exchange / Ticker: NASDAQ CVKD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Axim Biotechnologies Inc

The Diminishing Returns have widen more at the Axim Biotechnologies Inc in the October to December 31 2023 fiscal time-frame

For the October to December 31 2023 fiscal time-frame AXIM increased a deficit per share of $-0.02 per share compare to $0.00 a year prior and from $0.00 per share from the preceding financial reporting period. The revenue grew strongly by 66.79 % to $0.01 million from $0.01 million in the corresponding financial reporting period a year prior and sequentially revenue surged by 31.625 % from $0.01 million.

Neximmune Inc

The company reported operating loss in the fourth quarter of 2023

While the October to December 31 2023 reporting cycle goes on, many corporations have reported the results. Among them, are many constituents of the Major Pharmaceutical Preparations sector. And today, NEXI reported operating loss of $-5.367787 million, for the fiscal fourth quarter of 2023.

Hepion Pharmaceuticals Inc

Working expenses were increasing at the company in the October to December 31 2023 financial span

The Major Pharmaceutical Preparations industry experts start to scrutinize the fourth quarter of 2023 performance. Presently they observe operating deficit of $-10.408594 million, from the HEPA, which has not stated any revenue thus far, for the respective October to December 31 2023 quarter.

Cnbx Pharmaceuticals Inc

Cnbx Pharmaceuticals Inc Surges Ahead with Revenue Growth of $0.040637 Million

Cnbx Pharmaceuticals Inc Sets Positive Financial Trend with Revenue Growth
In an impressive financial turnaround, Cnbx Pharmaceuticals Inc announced a revenue of $0.040637 million for the financial period ending on February 29, 2024. This remarkable figure reflects a substantial increase from the corresponding quarter a year ago, signaling positive momentum for the pharmaceutical company.
Even more notable is the company's net shortfall of only $-0.325 million, a stark contrast to the $-2.624 million deficit reported in the same quarter last year. This astonishing reduction in losses underlines Cnbx Pharmaceuticals Inc's commitment to improving operational efficiency and financial stability.

Connect Biopharma Holdings Limited

The ascending corporation from the Major Pharmaceutical Preparations industry the CNTB released the financial interval ending fourth quarter of 2023, numbers

As the October to December 31 2023 reporting season continues, many corporations have declared the numbers. Among them, are multiple constituents of the Major Pharmaceutical Preparations sector. And now, CNTB announced operating loss of $-62.074 million, for the October to December 31 2023 three months.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com